Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

Barbara McGowan, Jens Meldgaard Bruun, Matt Capehorn, Sue D. Pedersen, Kirsi H. Pietiläinen, Hanna Angelene Kudiyanur Muniraju, Maria Quiroga, Anette Varbo, David C.W. Lau